Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Login Sign up free
Home Stock ScreenerScreener ETF ScreenerETF Maps Charts News Groups Insider Futures Forex Crypto Watchlist Portfolio Calendar
Pricing

DTIL

Precision Biosciences Inc

Last Close
10.28
Nov 05 • 3:42 PM ET Dollar change+2.16 Percentage change(26.60%)
Overview Compare Short Interest Financials Options Filings Dilution
Healthcare Biotechnology USA Micro NASD
Today, 7:18 AMPrecision BioSciences DSMB finds no safety concerns, authorizes dosing of additional patients in Phase 1/2 FUNCTION-DMD trial
Peers: EDIT PRME ABUS NTLA SCTX BEAM CRBU ALGS SLDB VIR
 | Held by: IWM VTI VXF IWN FESM VTWO IWC AVSC GSSC DFAS
Scroll to Statements
Index
RUT
Market Cap
287.18M
Enterprise Value
233.05M
Income
-39.43M
Sales
45.04M
Book/sh
1.86
Cash/sh
2.93
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
68
IPO
Mar 28, 2019
P/E
-
Forward P/E
-
PEG
-
P/S
6.38
P/B
5.54
P/C
3.51
P/FCF
-
EV/EBITDA
-
EV/Sales
5.17
Quick Ratio
10.47
Current Ratio
10.47
Debt/Eq
0.54
LT Debt/Eq
0.50
Option/Short
Yes / Yes
EPS (ttm)
-1.28
EPS next Y
-2.76
EPS next Q
-0.74
EPS this Y
11.35%
EPS next Y
12.63%
EPS next 5Y
18.51%
EPS past 3/5Y
54.31% 43.45%
Sales past 3/5Y
10.93% 7.13%
EPS Y/Y TTM
84.80%
Sales Y/Y TTM
6353.01%
EPS Q/Q
84.99%
Sales Q/Q
-100.00%
Earnings
Nov 03 BMO
EPS/Sales Surpr.
67.06% -100.00%
Insider Own
13.49%
Insider Trans
0.13%
Inst Own
66.72%
Inst Trans
4.86%
ROA
-36.87%
ROE
-115.28%
ROIC
-50.66%
Gross Margin
94.45%
Oper. Margin
-80.27%
Profit Margin
-87.54%
SMA20
49.32%
SMA50
49.83%
SMA200
55.31%
Trades
Shs Outstand
27.89M
Shs Float
23.88M
Short Float
9.87%
Short Ratio
9.31
Short Interest
2.36M
52W High
9.62 6.86%
52W Low
3.53 191.22%
Volatility
8.73% 7.40%
ATR (14)
0.70
RSI (14)
79.66
Beta
1.36
Rel Volume
10.86
Avg Volume
253.04K
Volume
2,628,209
Perf Week
38.17%
Perf Month
64.48%
Perf Quarter
37.25%
Perf Half Y
37.43%
Perf YTD
147.12%
Perf Year
55.29%
Perf 3Y
-19.49%
Perf 5Y
-96.48%
Perf 10Y
-
Recom
1.00
Target Price
29.40
Prev Close
8.12
Price
10.28
Change %
26.60%
Consensus
Strong Buy
Avg. Price Target
$29.40
Implied Upside
+186.0%
Analysts11incl. previous ratings
Rating Distribution9 Buy · 2 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jun 09, 2026Initiated
OPY logoOOppenheimer
Outperform$20+94.6%
Jan 10, 2025Upgrade
BMO logoBBMO Capital Markets
Market Perform → Outperform$34+230.7%
Apr 30, 2024Initiated
GGuggenheim
Buy$19+84.8%
Jun 17, 2022Initiated
BMO logoBBMO Capital Markets
Outperform$7-31.9%
Jun 09, 2022Downgrade
WWilliam Blair
Outperform → Mkt Perform
Jul 27, 2020Resumed
BBTIG Research
Buy$16+55.6%
Apr 03, 2020Downgrade
GS logoGGoldman
Buy → Neutral$24 → $7-31.9%
Mar 05, 2020Initiated
SF logoSStifel
Buy$21+104.3%
Feb 25, 2020Initiated
WWilliam Blair
Outperform
Aug 09, 2019Initiated
BBTIG Research
Buy$22+114.0%
Show Previous News
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Frankel StanleyDirectorSep 28 '26Buy6.001,0006,00041,478Sep 30 04:15 PM
Brown MelindaDirectorSep 25 '26Buy6.271,1357,11645,481Sep 29 07:00 AM
Germano Geno JDirectorSep 25 '26Buy6.282,60916,38547,492Sep 29 07:00 AM
Amoroso MichaelPresident and CEOFeb 17 '26Option Exercise0.0067,7970263,951Feb 19 04:31 PM
Amoroso MichaelPresident and CEOFeb 18 '26Sale3.8420,55978,947243,392Feb 19 04:31 PM
Kelly John AlexanderChief Financial OfficerFeb 17 '26Option Exercise0.0027,5840134,032Feb 19 04:31 PM
Kelly John AlexanderChief Financial OfficerFeb 18 '26Sale3.848,14931,292125,883Feb 19 04:31 PM
Scimeca DarioGeneral Counsel and SecretaryFeb 17 '26Option Exercise0.0016,667061,382Feb 19 04:30 PM
Scimeca DarioGeneral Counsel and SecretaryFeb 18 '26Sale3.844,92518,91256,457Feb 19 04:30 PM
SMITH J. JEFFERSONChief Research OfficerFeb 17 '26Option Exercise0.0016,6670126,851Feb 19 04:30 PM
SMITH J. JEFFERSONChief Research OfficerFeb 18 '26Sale3.844,92518,912121,926Feb 19 04:30 PM
SMITH J. JEFFERSONOfficerFeb 18 '26Proposed Sale3.844,92518,929Feb 18 05:05 PM
Scimeca DarioOfficerFeb 18 '26Proposed Sale3.844,92518,929Feb 18 04:31 PM
Amoroso MichaelOfficerFeb 18 '26Proposed Sale3.8420,55979,019Feb 18 04:30 PM
Kelly John AlexanderOfficerFeb 18 '26Proposed Sale3.848,14931,321Feb 18 04:19 PM
Amoroso MichaelPresident and CEOJan 22 '26Sale4.1734,799145,112196,154Jan 22 06:49 PM
Scimeca DarioGeneral Counsel and SecretaryJan 20 '26Option Exercise0.0025,311053,569Jan 22 06:48 PM
Scimeca DarioGeneral Counsel and SecretaryJan 21 '26Sale4.038,85435,68244,715Jan 22 06:48 PM
Kelly John AlexanderChief Financial OfficerJan 21 '26Sale4.0315,21361,308106,448Jan 22 06:48 PM
SMITH J. JEFFERSONChief Research OfficerJan 21 '26Sale4.0310,20041,106110,184Jan 22 06:48 PM
Amoroso MichaelOfficerJan 22 '26Proposed Sale4.1734,799145,202Jan 22 03:19 PM
Scimeca DarioOfficerJan 21 '26Proposed Sale4.038,85435,653Jan 21 04:19 PM
SMITH J. JEFFERSONOfficerJan 21 '26Proposed Sale4.0310,20041,073Jan 21 04:14 PM
Kelly John AlexanderOfficerJan 21 '26Proposed Sale4.0315,21361,260Jan 21 04:07 PM
Germano Geno JDirectorDec 16 '25Buy4.723,00014,16023,883Dec 17 07:02 AM
Frankel StanleyDirectorDec 16 '25Buy4.702,70012,69019,478Dec 17 07:01 AM
Brown MelindaDirectorDec 15 '25Buy4.971,3816,86423,346Dec 17 07:00 AM
Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's proprietary genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane on January 26, 2006 and is headquartered in Durham, NC.
PresidentMr. Michael Amoroso
Chief Operating OfficerMr. John Alexander Kelly R.Ph.
Chief Legal Officer & SecretaryMr. Dario Scimeca J.D.
Co-Founder & Chief Research OfficerDr. Jefferson J. Smith Ph.D.
Chief Financial OfficerMr. Naresh Tanna
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Affiliate • Advertise • APIs • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)